Clinical trials · Raleigh–Durham, NC
Cancer clinical trials in Raleigh–Durham
We’re tracking 429 recruiting cancer studies with a site in or near Raleigh–Durham — including Phase 1, Phase 1/Phase 2, Phase 2, Phase 2/Phase 3 and Phase 3 studies, each written for real people, not researchers.
Recruiting studies near Raleigh–Durham
- NCT06022822RecruitingPhase 2
Urolithin A supplement before prostate cancer surgery
This trial tests whether taking a supplement called urolithin A for a few weeks before prostate removal surgery can help. The supplement comes from pomegranates and may slow cancer growth. You may qualify if you have prostate cancer, are planning surgery within 3-6 weeks, and have not had prior treatment like hormone therapy.
Durham, North CarolinaAges 18 years+ - NCT07023289RecruitingPhase 2
Study of Telisotuzumab Adizutecan for ctDNA-Positive Colorectal Cancer
This trial tests a new drug, Telisotuzumab Adizutecan, given through a vein (infusion) alone or with standard treatments for people with colorectal cancer who have no visible tumors on scans but still have cancer DNA (ctDNA) in their blood after surgery and chemotherapy.
Durham, North CarolinaAges 18 years+ - NCT05675410RecruitingPhase 3
Testing two-drug treatment versus standard for Hodgkin lymphoma
This Phase 3 study compares today’s standard treatment for classic Hodgkin lymphoma with a new combination using brentuximab vedotin and nivolumab. The goal is to see which approach works better and is safe for newly diagnosed patients with early-stage disease.
Durham, North CarolinaAges 5–60 - NCT05554406RecruitingPhase 2
New drug therapy for high-risk AML
This trial is testing new drug combinations for people with newly diagnosed, high-risk AML who have not yet started treatment. It aims to find more effective therapies for this aggressive form of leukemia.
Durham, North CarolinaAges 18–59 - NCT05208047RecruitingPhase 3
CGT9486 plus sunitinib for advanced gastrointestinal stromal tumors
This trial tests whether adding a new drug called CGT9486 to sunitinib (a standard cancer drug) works better than sunitinib alone for gastrointestinal stromal tumors (GISTs) that have grown or spread. You may qualify if your GIST stopped responding to or caused problems with imatinib, an earlier treatment.
Durham, North CarolinaAges 18 years+ - NCT04585750RecruitingPhase 1/Phase 2
Studying a new drug for cancers with a specific TP53 change
This trial tests a new drug (rezatapopt) for people with advanced cancers that have a specific change in the TP53 gene, called Y220C. The drug is designed to target this change and may slow or stop cancer growth. Some participants may also receive an immunotherapy drug called pembrolizumab (Keytruda).
Durham, North CarolinaAges 12 years+ - NCT05564390RecruitingPhase 2
MyeloMATCH screening to match you to AML or MDS treatment
This study screens people with newly suspected acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) to see which treatment approach fits best—either a specific study treatment or standard care. It may help by directing you to the right option and by sharing your blood/bone marrow samples for research.
Durham, North CarolinaAges 18 years+ - NCT06492616RecruitingPhase 3
Elacestrant versus standard hormone therapy for early breast cancer
This trial compares a new medicine, elacestrant, to the usual hormone therapy for people with early-stage breast cancer that is hormone receptor-positive and HER2-negative, and who have a high chance of it coming back. The goal is to see if elacestrant works better at preventing the cancer from returning.
Durham, North CarolinaAges 18 years+ - NCT06896474Recruiting
Breast cancer treatment choice help for women 70 and older
This study tests a decision aid to help women 70 and older with early stage breast cancer choose their treatment. It looks at whether the tool helps patients and their doctors make a confident treatment choice.
Durham, North CarolinaAges 18 years+ - NCT06512350Recruiting
Breath test for breast cancer patterns
This study is testing whether a simple breath test can help find patterns linked to breast cancer. If you are scheduled for a breast biopsy or MRI, you may be eligible to participate.
Durham, North CarolinaAges 40–74 - NCT06515613RecruitingPhase 1
Testing CTIM-76 for recurrent ovarian and other advanced cancers
This trial tests a new drug, CTIM-76, in people whose ovarian, testicular, or endometrial cancer has come back and is not responding to standard treatments. It aims to see if the drug can shrink tumors or stop them from growing.
Durham, North CarolinaAges 18 years+ - NCT06532773Recruiting
Mindfulness for better sleep during blood cancer treatment
This study tests whether learning mindfulness (a way of focusing attention and calming the mind) can help improve sleep and manage symptoms for people with blood cancers who are in the hospital. It may give you coping skills to feel better during and after your treatment.
Durham, North CarolinaAges 18 years+ - NCT04613596RecruitingPhase 2/Phase 3
Adagrasib for KRAS G12C lung cancer, alone or with pembrolizumab
This trial studies adagrasib (an anti-cancer drug) either alone or with pembrolizumab (an immunotherapy) in people with advanced lung cancer that has a KRAS G12C mutation. It aims to shrink tumors and improve outcomes, including for people without urgent brain treatment needs.
Durham, North CarolinaAges 18 years+ - NCT07085767RecruitingPhase 3
Palazestrant and ribociclib for first-line advanced breast cancer
This trial tests a new drug (palazestrant) combined with ribociclib for people with a common type of advanced breast cancer that is estrogen receptor-positive and HER2-negative. You may qualify if you haven't had treatment for advanced disease and your cancer has either just been found or came back long after completing hormone therapy.
Durham, North CarolinaAges 18 years+ - NCT04929223RecruitingPhase 1
Targeted drug study for metastatic colon or rectal cancer
This Phase 1 study tests targeted cancer treatments in people with metastatic colorectal cancer, using genetic “biomarker” results to match you to the right treatment group. It focuses first on safety, and also looks for early signs the treatment may work in specific tumor subgroups.
Durham, North CarolinaAges 18 years+ - NCT05365581RecruitingPhase 1
Study drug for stomach and pancreatic cancers with lab-checked targets
This Phase 1 trial tests ASP2138 alone or with other cancer medicines in adults with stomach (including GEJ) or pancreatic cancer. You may be eligible if your tumor has a specific protein marker and your health tests and scan results meet safety requirements.
Durham, North CarolinaAges 18 years+ - NCT06616584RecruitingPhase 2/Phase 3
Cemiplimab plus standard care for advanced lung cancer after prior treatments
This trial tests whether adding the immunotherapy drug cemiplimab to standard treatment can help people with advanced lung cancer that has already progressed after both platinum chemo and a prior immunotherapy. It is designed for those who responded to their first immunotherapy for at least 12 weeks before the cancer started growing again.
Durham, North CarolinaAges 18 years+ - NCT06253871RecruitingPhase 1
Study of IAM1363 for HER2 Cancers
This trial tests a new oral drug called IAM1363 for people with HER2-altered cancers that have stopped responding to previous treatments. The goal is to see if the drug is safe and how well it works against these cancers.
Durham, North CarolinaAges 18 years+ - NCT03860883Recruiting
Comparing wider versus narrower surgery margins for stage II melanoma
This trial studies whether removing a slightly wider strip of skin around a melanoma improves outcomes compared with a narrower strip. It also uses a lymph node staging procedure to check spread and helps doctors fine-tune surgery for stage II melanoma.
Durham, North CarolinaAges 18 years+ - NCT04858256RecruitingPhase 2
Pacritinib for relapsed or resistant T-cell blood cancers
This Phase 2 trial studies pacritinib, an oral medicine, for T-cell lymphoma/leukemia that has come back or did not respond to prior treatment. It aims to see how well pacritinib can control the cancer and improve outcomes.
Durham, North CarolinaAges 18 years+ - NCT06549465RecruitingPhase 2
Ac-225 rosopatamab for PSMA-positive castration-resistant prostate cancer
This trial tests a radioactive drug (Ac-225 rosopatamab tetraxetan) that targets a protein called PSMA on prostate cancer cells. It is for patients whose cancer has stopped responding to hormone therapy and has spread to other parts of the body.
Durham, North CarolinaAges 18 years+ - NCT07525206RecruitingPhase 3
Combination treatment for advanced colorectal cancer
This trial tests a new drug combination for colorectal cancer that has not responded to other treatments. It compares the new drug with a standard treatment to see which is more effective.
Durham, North CarolinaAges 18 years+ - NCT06649812RecruitingPhase 2
Testing a combination targeted therapy (ViPOR) for aggressive B-cell lymphoma
This trial tests a new combination of targeted drugs called ViPOR for people with aggressive B-cell lymphoma that has come back or not responded to previous treatment. The goal is to see if this treatment can help when standard therapies haven't worked.
Durham, North CarolinaAges 18 years+ - NCT06658912Recruiting
Weight loss program for breast cancer survivors
This study tests a weight loss program designed specifically for women who have finished breast cancer treatment. It aims to help improve overall health after cancer.
Durham, North CarolinaAges 21–90
Hear when a new Cancer trial opens near Raleigh–Durham, NC
We’ll email you when one opens near Raleigh–Durham, NC — at most once a week, no account needed, unsubscribe anytime.
Cancer trials in other cities
Where these studies are running near Raleigh–Durham
Institutions with a site for the recruiting cancer studies listed above.
- Duke University Medical Center · 18 studies
- UNC Lineberger Comprehensive Cancer Center · 2 studies
- 2400 Pratt Street
- Clinical Trial Site
- Duke Children's Hospital and Health Center
- Duke University Medical Cente
- Duke University Medical Center /ID# 279322
- Durham VA Medical Center
What taking part in a cancer study involves
A screening visit first
Before anything else, the study team checks whether you fit — usually a visit with some tests. You can stop at any point, and screening is typically free.
Care at a nearby site
Study visits happen at a clinic or hospital taking part. Many studies cover the cost of the study treatment and related visits, and some reimburse travel.
You stay in control
Taking part is voluntary and you can leave a study at any time, for any reason, without affecting your regular care.
The team decides eligibility
Our fit check is a helpful first read, not a decision. The study team makes the final call after reviewing your health history.
Looking wider? See all recruiting cancer studies in North Carolina.
Common questions
- Are there cancer clinical trials near Raleigh–Durham?
- Yes. We're currently tracking 429 recruiting cancer studies with a site near Raleigh–Durham, each rewritten in plain language so you can see what it's testing and who it's for.
- How do I find out if I qualify for a cancer study near Raleigh–Durham?
- Each study lists its eligibility rules — age, diagnosis, prior treatments. On every trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Do I have to live in Raleigh–Durham to take part?
- Not necessarily. These studies have a site near Raleigh–Durham, but eligibility is about your health, not your address — some people travel to take part, and a few studies reimburse travel. The study team can tell you what's required.
- Does it cost anything to join a cancer trial?
- Using Clin2 is always free. Many trials cover the study treatment and related visits; some reimburse travel. The study team explains exactly what's covered before you decide.
Not the right time?
New cancer studies open near Raleigh–Durham regularly. Set up a health profile and we’ll quietly watch for studies that fit you and email you when one opens.